Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Recombinant DNA01:09

Recombinant DNA

Overview
Cross-reactivity00:42

Cross-reactivity

Overview
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

Shaping the Future of Respiratory Care: A Look Into the Next Decade and Strategic Recommendations by the European Forum for Research and Education in Allergy and Airways Diseases.

Chest·2026
Same author

Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024.

Frontiers in allergy·2025
Same author

EUFOREA summit in Brussels 2023: <i>inspiring the future of allergy & respiratory care</i>.

Frontiers in allergy·2023
Same author

How to integrate atopic dermatitis in the management of skin neglected tropical diseases in Sub-Saharan Africa?

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Position statement: Recommendations on the diagnosis and treatment of Malassezia folliculitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Related Experiment Video

Updated: Jun 7, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

[Recombinant allergens. For routine use or still only science?].

P Schmid-Grendelmeier1

  • 1Dermatologische Klinik, Universitätsspital, Gloriastr. 31, 8091, Zürich, Schweiz. peter.schmid@usz.ch

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|October 29, 2010
PubMed
Summary

Component-resolved diagnosis identifies specific allergy patterns, guiding targeted immunotherapy for conditions like allergic bronchopulmonary aspergillosis. This approach improves precision by detecting IgE against individual allergens, enhancing treatment efficacy.

More Related Videos

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Related Experiment Videos

Last Updated: Jun 7, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Area of Science:

  • Allergen immunotherapy
  • Immunology
  • Diagnostic methods

Context:

  • Component-resolved diagnosis (CRD) offers disease-specific sensitization patterns.
  • Pollen allergen IgE determination (e.g., Bet v 1, Ole e 1) aids immunotherapy guidance.
  • CRD identifies cross-reactivity, such as between birch pollen and PR10 proteins.

Purpose:

  • To explore the utility of component-resolved diagnosis in allergy management.
  • To highlight the role of IgE detection against specific allergens for precise diagnosis.
  • To discuss the clinical relevance of sensitizations to major and minor allergens.

Summary:

  • CRD detects IgE against specific allergens, improving diagnosis for allergic bronchopulmonary aspergillosis (ABPA) and other conditions.
  • Sensitization to major pollen allergens guides immunotherapy, while minor allergens (profilins, polcalcins) have limited clinical relevance.
  • CRD identifies food allergies with cross-reactivity and predicts severe reactions to storage proteins (e.g., Ara h 2, Pru p 3, Cor a 8).
  • It is also useful for exercise-induced anaphylaxis, latex sensitization, and insect allergies.
  • Microarray-based allergen chip diagnosis enables detection of IgE against numerous allergens but requires further optimization.

Impact:

  • Enables more precise allergen-specific immunotherapy, improving treatment outcomes.
  • Facilitates identification of clinically relevant allergens and cross-reactivities.
  • Provides valuable diagnostic information for complex allergic conditions and severe reactions.
  • Advances diagnostic capabilities through emerging technologies like microarray-based allergen chips.